‘Ticking time bomb': Ocean acidity crosses vital threshold, study finds
Nearly two-thirds of the ocean below 200 meters, or 656 feet, as well as nearly half of that above, have breached 'safe' levels of acidity, according to findings published on Monday in Global Change Biology.
The fall in ocean pH is 'a ticking time bomb for marine ecosystems and coastal economies,' Steve Widdicombe, director of science at the United Kingdom's Plymouth Marine Laboratory (PML), said in a statement.
The study was funded in part by the National Oceanographic and Atmospheric Administration (NOAA), a federal agency that has been targeted for steep cuts by the Trump White House, in large part because of its role in investigating climate change.
Some of the biggest changes in deep water are happening off the coast of western North America, home to extensive crab and salmon fisheries, the study found.
The core problem is one scientists have warned about for a long time: the continued global burning of fossil fuels, which releases carbon dioxide — an acid when dissolved in water — is making the seas and oceans more acidic.
Or, technically, it's making them less basic, which is to say: Less hospitable to species such as corals and clams that form the foundation of the ocean's ecosystem.
'Most ocean life doesn't just live at the surface — the waters below are home to many more different types of plants and animals,' lead author Helen Findlay of PML. 'Since these deeper waters are changing so much, the impacts of ocean acidification could be far worse than we thought.'
As of five years ago, Findlay's study noted, the oceans may have crossed a critical threshold in which oceanic levels of calcium carbonate — the main ingredient in limestones, and also the shells of those animals — fell to more than 20 percent below pre-industrial levels.
If true, that shift would mean the Earth has passed seven out of nine of the critical 'planetary boundaries' needed to maintain its ecosystem, as the Potsdam Institute for Climate Impact Research found last year.
That shift, Widdicombe of the Marine Lab said, means 'we're witnessing the loss of critical habitats that countless marine species depend on.'
'From the coral reefs that support tourism to the shellfish industries that sustain coastal communities,' he added, 'we're gambling with both biodiversity and billions in economic value every day that action is delayed.'
The further implications are even more serious. The reasons for the ocean's rise in acid, or fall in base, is that its waters have absorbed about one-third of all the carbon dioxide released by surface burning of coal, oil and gas.
But the more carbon dioxide it absorbs, the lower its ability to absorb more — meaning faster warming on the surface.
Making that dynamic even more dramatic, seas and oceans have also absorbed 90 percent of the global heating that the Earth's surface would have otherwise experienced, according to NASA.
In addition to absorbing heat and carbon dioxide, the ocean also provides 50 percent of the Earth's oxygen — which comes from the very marine ecosystems that warming and acidification are threatening.
Ecosystem loss and fossil fuel burning mean that levels of oxygen below the surface are decreasing, as, more slowly, is oxygen above the surface.
—Updated at 12:37 p.m. EDT
Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
29 minutes ago
- Yahoo
AbCellera Biologics (ABCL) Advances Proprietary Pipeline with Promising Phase 1 Trial Results
We recently published . AbCellera Biologics Inc. (NASDAQ:ABCL) is one of the best healthcare stocks. AbCellera Biologics Inc. (NASDAQ:ABCL) is a biotech company specializing in discovering and developing therapeutic antibodies across various disease areas, including cancer, metabolic, endocrine, and autoimmune disorders. Their integrated platform combines technology, data science, and collaboration to identify promising antibody candidates. In recent developments, AbCellera Biologics Inc. (NASDAQ:ABCL) began dosing participants in a Phase 1 clinical trial for ABCL635, targeting vasomotor symptoms related to menopause, marking a key clinical milestone. The company reported strong Q2 2025 revenue growth, beating expectations and advancing both internal and partnered antibody programs despite ongoing net losses. Some analysts note that its innovative pipeline and expanding clinical presence could place it among the best healthcare stocks to watch in the biotech space. Photo by Myriam Zilles on Unsplash This Phase 1 trial signals the corporation's shift from primarily a discovery platform to a clinical-stage biotech with proprietary assets. Progress with ABCL635 addresses a significant unmet medical need and validates its platform's potential to develop first-in-class therapeutics. While we acknowledge the potential of ABCL as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money. Disclosure: None. Sign in to access your portfolio


The Hill
11 hours ago
- The Hill
Samples before space suits: America must be smart about its mission to Mars
On day one of this administration, the president included his ambitions for Mars in his inaugural address, and again several weeks later to a joint session of Congress: 'We are going to conquer the vast frontiers of science, and we are going to lead humanity into space and plant the American flag on the planet Mars, and even far beyond.' President Trump's vision for Mars is correct, and now there is a plan for the next steps in how he achieves it. The U.S. has led the world in the exploration of Mars since Vikings I and II landed in 1976. We now stand on the precipice of two ultimate achievements: the return of samples from Mars to Earth, and sending the first humans — Americans — to the Martian surface. The fiscal 2026 presidential budget request proposed 'to terminate the Mars Sample Return Program given that current architecture options remain unaffordable.' But, it adds: 'It is anticipated that future missions to Mars will return samples for study on Earth.' We need those samples robotically returned for study on Earth. Delaying Mars Sample Return or waiting for astronauts to pick them up will make the human exploration of Mars significantly more expensive and dangerous — and for the first time ever, almost certainly cede decades of U.S. space exploration leadership to China. A lower-cost robotic Mars Sample Return would more than pay for itself from savings realized by simplified human missions. Martian soil has substances known to be toxic, as well as uncharacterized biological potential. Without Mars Sample Return, human mission designs must account for the full range of possibilities and the most demanding scenarios. Laboratory tests are needed to make direct measurements of the Mars samples to determine concentrations and forms of toxic materials to understand threats and develop solutions. This will be needed to design spacesuits and protect astronauts from the fine martian dust. It allows risk mitigation to shift from large and expensive requirements to quantifiable ones with reduced uncertainties. While no martian life has been detected yet, our exploration has shown that much of Mars would previously have been habitable, and parts of Mars may currently still be habitable. In advance of humans to Mars, we need to robotically return samples in a highly controlled manner to satisfy planetary protection back-contamination requirements to ensure that Mars does not have organisms that might impact human health or have adverse effects on Earth's biosphere. Mars Sample Return will accelerate U.S. leadership in space. Mars is several hundred times farther from Earth than the Moon. Using current propulsion technologies, a Mars round trip will take up to three years, with minimal abort opportunities, as compared to Apollo's round trip of days. Even then, there were three uncrewed and four crewed missions before Apollo 11, the first Moon landing. Completing Mars Sample Return supports technology demos needed for human missions, such as advancing from the current precision landing (7-10 km) to pinpoint landing (~100 m) to put astronauts in proximity to safe sites and pre-positioned supplies. Mars Sample Return also achieves a profound international first: the first samples — with potential for evidence of life — returned from Mars. These samples might once and for all answer the fundamental question of 'Are we alone in the universe,' and that is a question we most certainly want the United States to answer first. Lockheed Martin, my former employer, has been studying Mars Sample Return missions for more than 50 years, and is confident it can deliver an end-to-end architecture for under $3 billion — less than half of previous estimates — by leveraging heritage components, reducing design complexity, and streamlining the program structure. They have built and flown four highly successful Mars landers and four highly successful Mars orbiters, as well as pioneered all three of NASA's previous sample return missions (returning material from a comet, the solar wind and an asteroid), and have established credibility and mission success across a wide variety of additional deep space missions, from Venus to Saturn. NASA's Mars 2020 rover, Perseverance or 'Percy,' at Jezero Crater has been caching an unparalleled set of samples that will shed more light on the history of Mars than all previous Mars missions combined. China has announced it plans to launch a sample return mission to Mars in 2028, with an Earth return likely in 2031. If we forgo the timely return of Percy's superior set of samples, it will be China that leaps ahead. Mars soil and dust are uniquely different, and potentially dangerous — returning samples should precede astronauts going to Mars, while also maintaining our nation's pre-eminence in Mars exploration as NASA lays the groundwork for the next giant leap. Ben Clark has been a member of the science teams of every NASA mission to explore the surface of Mars, and designed the instrument on Viking that made the first analysis of martian soil. He was chief scientist for deep space exploration at Lockheed Martin. Currently, he helps analyze chemical compositions of the diverse samples the Perseverance rover has been acquiring during its multi-year trek on Mars.


New York Times
18 hours ago
- New York Times
China's Biotech Is Cheaper and Faster
Just outside of Shanghai, in the city of Wuxi, China is building its future of medicine — a booming biotechnology hub of factories and laboratories where global pharmaceutical companies can develop and manufacture drugs faster and cheaper than anywhere else. Amid the Trump administration's tariffs on China, I figured manufacturing hubs like this one would be wracked with anxiety. But when I visited Wuxi in April, government officials insisted that its research hub was flourishing. They were proud to tell me about their superstar labs and companies that are continuing to thrive. The fact that Chinese biotechnology stocks have surged over 60 percent since January seems to bolster this claim. The city's researchers certainly seemed positioned to be busy for decades. In its quest to dethrone American dominance in biotech, China isn't necessarily trying to beat America at its own game. While the U.S. biotech industry is known for incubating cutting-edge treatments and cures, China's approach to innovation is mostly focused on speeding up manufacturing and slashing costs. The idea isn't to advance, say, breakthroughs in the gene-editing technology CRISPR; it's to make the country's research, development, testing and production of drugs and medical products hyperefficient and cheaper. As a result, China's biotech sector can deliver drugs and other medical products to customers at much cheaper prices, including inexpensive generics. These may not be world-changing cures, but they are treatments that millions of people around the world rely on every day. And as China's reach expands, the world will soon have to reckon with a new leader in biotech and decide how it wants to respond. One such company that embodies the Chinese approach to biotech is Wuxi AppTec. It's a one-stop shop for pharmaceutical research and development, streamlining everything from early-stage drug discovery to young scientist recruitment and medication production. The company, whose clients have included Chinese firms like Innovent and Jiangsu Hengrui, as well as American and European drugmakers like Pfizer, GlaxoSmithKline and AstraZeneca, was involved in, by one estimate, a quarter of the drugs used in the United States, including blockbuster cancer drugs. Though the Chinese government bargains hard with both foreign and domestic pharmaceutical companies to provide products at the right price in exchange for market access, the low prices that Chinese consumers pay are ultimately the result of Chinese biotech companies' ability to test and manufacture drugs at a pace far faster than their American counterparts. So far, American biotech giants don't seem to mind the competition, since their own use of companies like Wuxi AppTec allows them to dedicate more of their money to breakthrough research. Want all of The Times? Subscribe.